Tag Archive for: Alzheimer’s disease

An experimental Alzheimer’s drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.

Researchers studying Alzheimer’s disease have published new studies supporting links between Alzheimer’s and other diseases, as well as potential risk factors for developing the disease later in life.

South Korea-based Genuv Inc. announced the publication of a preclinical study showing that Mekinist (trametinib), approved by the FDA for melanoma, has a neuroprotective effect in Alzheimer’s disease. 

With an investment valued at up to $1.1 billion, Merck is diving back into Alzheimer’s research through a collaboration with Cerevance.

“We are disappointed with this outcome. The treatment of Alzheimer’s disease psychosis continues to be an area of high unmet need, for which there is no approved therapy,” said company CEO Steve Davis.

Eli Lilly and Co. on Thursday cut its full-year profit forecast for the second time as lower insulin prices and competition for the company’s cancer drug bruised its second-quarter earnings.

Roche signed a $6 billion-plus collaboration deal with Poseida Therapeutics on blood cancers, while its Alzheimer’s partner, AC Immune, parsed failed data on an Alzheimer’s drug to suggest a positive spin.

The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc. involving whether the biotech company manipulated research results for its experimental Alzheimer’s drug, two people familiar with the inquiry said.

The U.S. Food and Drug Administration has agreed to review Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS), after the therapy failed a late-stage study but showed promise in some patients.

AbbVie has ended its collaboration deal with Alector to develop one of two potential Alzheimer’s disease drugs. However, the relationship isn’t totally severed between the pair as they are still working to develop AL002, which is focused on targeting triggering receptors expressed on myeloid cells 2 (TREM2) also for Alzheimer’s Disease.